The association of the COMT V158M polymorphism with endometrial/ovarian cancer in HNPCC families adhering to the Amsterdam criteria

Hereditary Cancer in Clinical Practice

Volumn 4, Issue 2, 2006, Pages 94-102

  Ashton, Katie A ^a   Meldrum, Cliff J ^b   McPhillips, Mary L ^b   Suchy, Janina ^c   Kurzawski, Grzegorz ^c   Lubinski, Jan ^c   Scott, Rodney J ^a,b,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c International Hereditary Cancer Center   (Poland)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Colorectal cancer; COMT V158M; Endometrial cancer; HNPCC; MMR; Mutations

Indexed keywords

CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; METHIONINE; PROTEIN MLH1; REACTIVE OXYGEN METABOLITE; VALINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ESTROGEN METABOLISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MISMATCH REPAIR; OVARY CANCER; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33745713720     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-4-2-94     Document Type: Article

References (31)

1. Watson P and Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 2001; 1: 57-60.
2. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP and de la Chapelle A. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-1487.
3. Peltomaki P, Gao P and Mecklin JR Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam Cancer 2001; 1: 9-15.
4. Mitchell RJ, Farrington SM, Dunlop MG and Campbell H. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 2002; 156: 885-902.
5. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H and van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91: 74-80.
6. Zhu BT and Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58: 2269-2277.
7. Cavalieri E, Frenkel K, Liehr JG, Rogan E and Roy D. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J Natl Cancer Inst Monogr 2000; (27): 75-93.
8. Yager JD and Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36: 203-232.
9. Dawling S, Roodi N, Mernaugh RL, Wang X and Parl FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001; 61: 6716-6722.
10. Service RF. New role for estrogen in cancer? Science 1998; 279: 1631-1633.
11. Erratum in: Science 1998; 280: 2033.
12. Inoue H, Shibuta K, Matsuyama A, Yoshinaga K, Sadanaga N, Ueo H, Barnard GF and Mori M. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncol Rep 2005; 14: 707-712.
13. Weinshilboum RM and Raymond FA. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 1977; 29: 125-135.
14. Lotto T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I and Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
15. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL and Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
16. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer SJ, Casey G and Witte JS. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006; [epub ahead of print].
17. Lin WY, Chou YC, Wu MH, Jeng YL, Huang HB, You SL, Chu TY, Chen CJ and Sun CA. Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: a nested case-control study in Taiwan. Cancer Detect Prev 2005; 29: 427-432. Epub 2005 Sep 26.
18. Garner EI, Stokes EE, Berkowitz RS, Mok SC and Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002; 62: 3058-3062.
19. Sellers TA, Schildkraut JM, Pankrate VS, Vierkant RA, Fredericksen ZS, Olson JE, Cunningham J, Taylor W, Liebow M, McPherson C, Hartmann LC, Pal T and Adjei AA. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (11 Pt 1): 2536-2543.
20. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM and Chen C. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 357-366.
21. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ and De Vivo I. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 2004; 25: 559-565. Epub 2003 Dec 4.
22. Sasaki M, Kaneuchi M, Sakuragi N and Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 2003; 63: 3101-3106.
23. Huber A, Bentz EK, Schneeberger C, Huber JC, Hefler L and Tempfer C. Ten polymorphisms of estrogen-metabolizing genes and a family history of colon cancer - an association study of multiple gene-gene interactions. J Soc Gynecol Investig 2005; 12:e51-54.
24. Mas S, Laso N, Lafuente MJ, Lafuente A, Molina R, Ballesta A, Zheng S and Wiencke JK. Cancer, genes, and catechol estrogen metabolites. Int J Clin Oncol 2003; 8: 65-66.
25. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F and Bellvitge Colorectal Cancer Study Group. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005; 15: 535-546.
26. Miller SA, Dykes DD and Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
27. Li Y, Yang X, van Breemen RB and Bolton JL. Characterization of two new variants of human catechol O-methyltransferase in vitro. Cancer Lett 2005; 230: 81-89.
28. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR and Collier DA. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996; 228: 780-784.
29. Denschlag D, Bentz EK, Hefler L, Pietrowski D, Zeillinger R, Tempfer C and Tong D. Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertil Steril 2006; 85: 462-467.
30. Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D and Cauley JA. Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 2005; 93: 261-270.
31. Comings DE and MacMurray JP Molecular heterosis: a review. Mol Genet Metab 2000; 71: 19-31.